Expleo Solutions Limited
Expleo Solutions Limited (EXPLEOSOL.BO) Stock Competitors & Peer Comparison
See (EXPLEOSOL.BO) competitors and their performances in Stock Market.
Peer Comparison Table: Information Technology Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| EXPLEOSOL.BO | ₹901.80 | -5.43% | 14B | 11.30 | ₹79.91 | N/A |
| TCS.NS | ₹2,308.20 | -0.82% | 8.4T | 17.05 | ₹135.91 | +4.70% |
| TCS.BO | ₹2,307.75 | -0.86% | 8.4T | 17.05 | ₹135.94 | +4.70% |
| INFY.BO | ₹1,168.65 | -1.10% | 4.8T | 16.84 | ₹69.73 | +3.83% |
| INFY.NS | ₹1,168.50 | -1.08% | 4.8T | 15.26 | ₹76.99 | +3.83% |
| HCLTECH.NS | ₹1,165.70 | -0.21% | 3.1T | 18.98 | ₹61.33 | +5.15% |
| HCLTECH.BO | ₹1,166.55 | -0.15% | 3.1T | 18.97 | ₹61.34 | +5.15% |
| WIPRO.NS | ₹206.84 | +3.55% | 2.1T | 16.17 | ₹12.56 | +5.42% |
| WIPRO.BO | ₹206.80 | +3.50% | 2.1T | 16.16 | ₹12.57 | +5.42% |
| LTIM.NS | ₹4,535.00 | +2.08% | 1.3T | 28.28 | ₹160.34 | +2.47% |
Stock Comparison
EXPLEOSOL.BO vs TCS.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, TCS.NS has a market cap of 8.4T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while TCS.NS trades at ₹2,308.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas TCS.NS's P/E ratio is 17.05. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to TCS.NS's ROE of +0.46%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to TCS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check TCS.NS's competition here
EXPLEOSOL.BO vs TCS.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, TCS.BO has a market cap of 8.4T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while TCS.BO trades at ₹2,307.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas TCS.BO's P/E ratio is 17.05. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to TCS.BO's ROE of +0.46%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to TCS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check TCS.BO's competition here
EXPLEOSOL.BO vs INFY.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, INFY.BO has a market cap of 4.8T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while INFY.BO trades at ₹1,168.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas INFY.BO's P/E ratio is 16.84. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to INFY.BO's ROE of +0.32%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to INFY.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check INFY.BO's competition here
EXPLEOSOL.BO vs INFY.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, INFY.NS has a market cap of 4.8T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while INFY.NS trades at ₹1,168.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas INFY.NS's P/E ratio is 15.26. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to INFY.NS's ROE of +0.32%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to INFY.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check INFY.NS's competition here
EXPLEOSOL.BO vs HCLTECH.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, HCLTECH.NS has a market cap of 3.1T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while HCLTECH.NS trades at ₹1,165.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas HCLTECH.NS's P/E ratio is 18.98. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to HCLTECH.NS's ROE of +0.23%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to HCLTECH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check HCLTECH.NS's competition here
EXPLEOSOL.BO vs HCLTECH.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, HCLTECH.BO has a market cap of 3.1T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while HCLTECH.BO trades at ₹1,166.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas HCLTECH.BO's P/E ratio is 18.97. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to HCLTECH.BO's ROE of +0.23%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to HCLTECH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check HCLTECH.BO's competition here
EXPLEOSOL.BO vs WIPRO.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, WIPRO.NS has a market cap of 2.1T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while WIPRO.NS trades at ₹206.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas WIPRO.NS's P/E ratio is 16.17. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to WIPRO.NS's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to WIPRO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check WIPRO.NS's competition here
EXPLEOSOL.BO vs WIPRO.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, WIPRO.BO has a market cap of 2.1T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while WIPRO.BO trades at ₹206.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas WIPRO.BO's P/E ratio is 16.16. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to WIPRO.BO's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to WIPRO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check WIPRO.BO's competition here
EXPLEOSOL.BO vs LTIM.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, LTIM.NS has a market cap of 1.3T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while LTIM.NS trades at ₹4,535.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas LTIM.NS's P/E ratio is 28.28. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to LTIM.NS's ROE of +0.21%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to LTIM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check LTIM.NS's competition here
EXPLEOSOL.BO vs TECHM.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, TECHM.NS has a market cap of 1.3T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while TECHM.NS trades at ₹1,435.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas TECHM.NS's P/E ratio is 26.22. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to TECHM.NS's ROE of +0.17%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to TECHM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check TECHM.NS's competition here
EXPLEOSOL.BO vs TECHM.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, TECHM.BO has a market cap of 1.3T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while TECHM.BO trades at ₹1,434.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas TECHM.BO's P/E ratio is 27.26. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to TECHM.BO's ROE of +0.17%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to TECHM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check TECHM.BO's competition here
EXPLEOSOL.BO vs LTIM.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, LTIM.BO has a market cap of 1.2T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while LTIM.BO trades at ₹3,930.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas LTIM.BO's P/E ratio is 25.03. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to LTIM.BO's ROE of +0.21%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to LTIM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check LTIM.BO's competition here
EXPLEOSOL.BO vs LTM.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, LTM.NS has a market cap of 1.2T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while LTM.NS trades at ₹3,991.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas LTM.NS's P/E ratio is 23.67. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to LTM.NS's ROE of +0.29%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to LTM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check LTM.NS's competition here
EXPLEOSOL.BO vs PERSISTENT.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, PERSISTENT.BO has a market cap of 777.3B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while PERSISTENT.BO trades at ₹5,037.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas PERSISTENT.BO's P/E ratio is 44.90. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to PERSISTENT.BO's ROE of +0.25%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to PERSISTENT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check PERSISTENT.BO's competition here
EXPLEOSOL.BO vs PERSISTENT.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, PERSISTENT.NS has a market cap of 776.5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while PERSISTENT.NS trades at ₹5,038.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas PERSISTENT.NS's P/E ratio is 41.78. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to PERSISTENT.NS's ROE of +0.25%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to PERSISTENT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check PERSISTENT.NS's competition here
EXPLEOSOL.BO vs COFORGE.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, COFORGE.NS has a market cap of 465.9B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while COFORGE.NS trades at ₹1,398.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas COFORGE.NS's P/E ratio is 31.68. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to COFORGE.NS's ROE of +0.20%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to COFORGE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check COFORGE.NS's competition here
EXPLEOSOL.BO vs COFORGE.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, COFORGE.BO has a market cap of 465.7B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while COFORGE.BO trades at ₹1,397.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas COFORGE.BO's P/E ratio is 31.66. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to COFORGE.BO's ROE of +0.20%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to COFORGE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check COFORGE.BO's competition here
EXPLEOSOL.BO vs MPHASIS.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, MPHASIS.BO has a market cap of 424.2B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while MPHASIS.BO trades at ₹2,244.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas MPHASIS.BO's P/E ratio is 23.57. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to MPHASIS.BO's ROE of +0.19%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to MPHASIS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check MPHASIS.BO's competition here
EXPLEOSOL.BO vs MPHASIS.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, MPHASIS.NS has a market cap of 424.1B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while MPHASIS.NS trades at ₹2,244.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas MPHASIS.NS's P/E ratio is 23.58. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to MPHASIS.NS's ROE of +0.19%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to MPHASIS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check MPHASIS.NS's competition here
EXPLEOSOL.BO vs LTTS.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, LTTS.BO has a market cap of 362.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while LTTS.BO trades at ₹3,547.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas LTTS.BO's P/E ratio is 29.55. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to LTTS.BO's ROE of +0.20%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to LTTS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check LTTS.BO's competition here
EXPLEOSOL.BO vs LTTS.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, LTTS.NS has a market cap of 362.5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while LTTS.NS trades at ₹3,546.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas LTTS.NS's P/E ratio is 29.51. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to LTTS.NS's ROE of +0.20%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to LTTS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check LTTS.NS's competition here
EXPLEOSOL.BO vs HEXT.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, HEXT.NS has a market cap of 313.3B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while HEXT.NS trades at ₹506.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas HEXT.NS's P/E ratio is 22.76. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to HEXT.NS's ROE of +0.23%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to HEXT.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check HEXT.NS's competition here
EXPLEOSOL.BO vs TATATECH.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, TATATECH.NS has a market cap of 272.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while TATATECH.NS trades at ₹677.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas TATATECH.NS's P/E ratio is 49.95. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to TATATECH.NS's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to TATATECH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check TATATECH.NS's competition here
EXPLEOSOL.BO vs TATATECH.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, TATATECH.BO has a market cap of 272.4B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while TATATECH.BO trades at ₹677.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas TATATECH.BO's P/E ratio is 49.70. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to TATATECH.BO's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to TATATECH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check TATATECH.BO's competition here
EXPLEOSOL.BO vs KPITTECH.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, KPITTECH.BO has a market cap of 204.5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while KPITTECH.BO trades at ₹756.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas KPITTECH.BO's P/E ratio is 32.27. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to KPITTECH.BO's ROE of +0.19%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to KPITTECH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check KPITTECH.BO's competition here
EXPLEOSOL.BO vs KPITTECH.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, KPITTECH.NS has a market cap of 204.5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while KPITTECH.NS trades at ₹756.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas KPITTECH.NS's P/E ratio is 32.28. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to KPITTECH.NS's ROE of +0.19%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to KPITTECH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check KPITTECH.NS's competition here
EXPLEOSOL.BO vs FSL.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, FSL.BO has a market cap of 185.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while FSL.BO trades at ₹280.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas FSL.BO's P/E ratio is 28.09. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to FSL.BO's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to FSL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check FSL.BO's competition here
EXPLEOSOL.BO vs FSL.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, FSL.NS has a market cap of 185.4B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while FSL.NS trades at ₹280.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas FSL.NS's P/E ratio is 28.07. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to FSL.NS's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to FSL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check FSL.NS's competition here
EXPLEOSOL.BO vs REDINGTON.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, REDINGTON.NS has a market cap of 172.8B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while REDINGTON.NS trades at ₹224.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas REDINGTON.NS's P/E ratio is 11.60. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to REDINGTON.NS's ROE of +0.16%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to REDINGTON.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check REDINGTON.NS's competition here
EXPLEOSOL.BO vs REDINGTON.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, REDINGTON.BO has a market cap of 172.5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while REDINGTON.BO trades at ₹224.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas REDINGTON.BO's P/E ratio is 11.57. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to REDINGTON.BO's ROE of +0.16%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to REDINGTON.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check REDINGTON.BO's competition here
EXPLEOSOL.BO vs ECLERX.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, ECLERX.BO has a market cap of 148.5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while ECLERX.BO trades at ₹1,586.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas ECLERX.BO's P/E ratio is 21.24. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to ECLERX.BO's ROE of +0.29%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to ECLERX.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check ECLERX.BO's competition here
EXPLEOSOL.BO vs ECLERX.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, ECLERX.NS has a market cap of 147B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while ECLERX.NS trades at ₹1,588.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas ECLERX.NS's P/E ratio is 21.21. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to ECLERX.NS's ROE of +0.29%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to ECLERX.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check ECLERX.NS's competition here
EXPLEOSOL.BO vs HEXAWARE.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, HEXAWARE.NS has a market cap of 141.4B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while HEXAWARE.NS trades at ₹470.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas HEXAWARE.NS's P/E ratio is 22.98. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to HEXAWARE.NS's ROE of +0.25%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to HEXAWARE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check HEXAWARE.NS's competition here
EXPLEOSOL.BO vs ZENSARTECH.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, ZENSARTECH.BO has a market cap of 111.2B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while ZENSARTECH.BO trades at ₹493.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas ZENSARTECH.BO's P/E ratio is 15.17. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to ZENSARTECH.BO's ROE of +0.18%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to ZENSARTECH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check ZENSARTECH.BO's competition here
EXPLEOSOL.BO vs ZENSARTECH.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, ZENSARTECH.NS has a market cap of 110.8B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while ZENSARTECH.NS trades at ₹493.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas ZENSARTECH.NS's P/E ratio is 14.51. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to ZENSARTECH.NS's ROE of +0.18%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to ZENSARTECH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check ZENSARTECH.NS's competition here
EXPLEOSOL.BO vs BSOFT.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, BSOFT.BO has a market cap of 91.7B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while BSOFT.BO trades at ₹330.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas BSOFT.BO's P/E ratio is 17.73. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to BSOFT.BO's ROE of +0.14%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to BSOFT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check BSOFT.BO's competition here
EXPLEOSOL.BO vs BSOFT.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, BSOFT.NS has a market cap of 91.7B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while BSOFT.NS trades at ₹330.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas BSOFT.NS's P/E ratio is 17.74. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to BSOFT.NS's ROE of +0.14%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to BSOFT.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check BSOFT.NS's competition here
EXPLEOSOL.BO vs SONATSOFTW.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, SONATSOFTW.BO has a market cap of 74.2B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while SONATSOFTW.BO trades at ₹273.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas SONATSOFTW.BO's P/E ratio is 16.02. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to SONATSOFTW.BO's ROE of +0.26%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to SONATSOFTW.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check SONATSOFTW.BO's competition here
EXPLEOSOL.BO vs SONATSOFTW.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, SONATSOFTW.NS has a market cap of 74.2B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while SONATSOFTW.NS trades at ₹274.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas SONATSOFTW.NS's P/E ratio is 15.99. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to SONATSOFTW.NS's ROE of +0.26%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to SONATSOFTW.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check SONATSOFTW.NS's competition here
EXPLEOSOL.BO vs RSYSTEMINT.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, RSYSTEMINT.BO has a market cap of 63.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while RSYSTEMINT.BO trades at ₹531.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas RSYSTEMINT.BO's P/E ratio is 106.05. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to RSYSTEMINT.BO's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to RSYSTEMINT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check RSYSTEMINT.BO's competition here
EXPLEOSOL.BO vs HAPPSTMNDS.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, HAPPSTMNDS.BO has a market cap of 55.5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while HAPPSTMNDS.BO trades at ₹373.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas HAPPSTMNDS.BO's P/E ratio is 30.04. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to HAPPSTMNDS.BO's ROE of +0.11%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to HAPPSTMNDS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check HAPPSTMNDS.BO's competition here
EXPLEOSOL.BO vs HAPPSTMNDS.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, HAPPSTMNDS.NS has a market cap of 55.5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while HAPPSTMNDS.NS trades at ₹373.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas HAPPSTMNDS.NS's P/E ratio is 30.04. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to HAPPSTMNDS.NS's ROE of +0.11%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to HAPPSTMNDS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check HAPPSTMNDS.NS's competition here
EXPLEOSOL.BO vs MASTEK.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, MASTEK.NS has a market cap of 50.7B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while MASTEK.NS trades at ₹1,670.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas MASTEK.NS's P/E ratio is 12.62. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to MASTEK.NS's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to MASTEK.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check MASTEK.NS's competition here
EXPLEOSOL.BO vs MASTEK.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, MASTEK.BO has a market cap of 50.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while MASTEK.BO trades at ₹1,671.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas MASTEK.BO's P/E ratio is 12.61. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to MASTEK.BO's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to MASTEK.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check MASTEK.BO's competition here
EXPLEOSOL.BO vs DATAMATICS.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, DATAMATICS.BO has a market cap of 46.5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while DATAMATICS.BO trades at ₹771.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas DATAMATICS.BO's P/E ratio is 23.86. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to DATAMATICS.BO's ROE of +0.14%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to DATAMATICS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check DATAMATICS.BO's competition here
EXPLEOSOL.BO vs DATAMATICS.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, DATAMATICS.NS has a market cap of 46.4B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while DATAMATICS.NS trades at ₹779.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas DATAMATICS.NS's P/E ratio is 23.83. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to DATAMATICS.NS's ROE of +0.14%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to DATAMATICS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check DATAMATICS.NS's competition here
EXPLEOSOL.BO vs ASMTEC.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, ASMTEC.BO has a market cap of 39B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while ASMTEC.BO trades at ₹3,276.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas ASMTEC.BO's P/E ratio is 78.95. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to ASMTEC.BO's ROE of +0.26%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to ASMTEC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check ASMTEC.BO's competition here
EXPLEOSOL.BO vs CAMS.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, CAMS.NS has a market cap of 37.5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while CAMS.NS trades at ₹769.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas CAMS.NS's P/E ratio is 39.66. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to CAMS.NS's ROE of +0.40%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to CAMS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check CAMS.NS's competition here
EXPLEOSOL.BO vs CAMS.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, CAMS.BO has a market cap of 37.5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while CAMS.BO trades at ₹769.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas CAMS.BO's P/E ratio is 39.54. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to CAMS.BO's ROE of +0.40%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to CAMS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check CAMS.BO's competition here
EXPLEOSOL.BO vs CIGNITITEC.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, CIGNITITEC.BO has a market cap of 34.8B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while CIGNITITEC.BO trades at ₹1,265.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas CIGNITITEC.BO's P/E ratio is 11.58. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to CIGNITITEC.BO's ROE of +0.31%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to CIGNITITEC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check CIGNITITEC.BO's competition here
EXPLEOSOL.BO vs CIGNITITEC.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, CIGNITITEC.NS has a market cap of 34.7B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while CIGNITITEC.NS trades at ₹1,260.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas CIGNITITEC.NS's P/E ratio is 11.54. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to CIGNITITEC.NS's ROE of +0.31%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to CIGNITITEC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check CIGNITITEC.NS's competition here
EXPLEOSOL.BO vs RSYSTEMS.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, RSYSTEMS.BO has a market cap of 31.9B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while RSYSTEMS.BO trades at ₹266.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas RSYSTEMS.BO's P/E ratio is 18.05. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to RSYSTEMS.BO's ROE of +0.26%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to RSYSTEMS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check RSYSTEMS.BO's competition here
EXPLEOSOL.BO vs RSYSTEMS.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, RSYSTEMS.NS has a market cap of 31.9B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while RSYSTEMS.NS trades at ₹267.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas RSYSTEMS.NS's P/E ratio is 15.64. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to RSYSTEMS.NS's ROE of +0.26%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to RSYSTEMS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check RSYSTEMS.NS's competition here
EXPLEOSOL.BO vs RPSGVENT.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, RPSGVENT.BO has a market cap of 30.1B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while RPSGVENT.BO trades at ₹931.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas RPSGVENT.BO's P/E ratio is -32.18. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to RPSGVENT.BO's ROE of -0.03%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to RPSGVENT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check RPSGVENT.BO's competition here
EXPLEOSOL.BO vs RPSGVENT.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, RPSGVENT.NS has a market cap of 30B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while RPSGVENT.NS trades at ₹932.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas RPSGVENT.NS's P/E ratio is -32.12. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to RPSGVENT.NS's ROE of -0.03%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to RPSGVENT.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check RPSGVENT.NS's competition here
EXPLEOSOL.BO vs SASKEN.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, SASKEN.NS has a market cap of 27.5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while SASKEN.NS trades at ₹1,924.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas SASKEN.NS's P/E ratio is 51.24. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to SASKEN.NS's ROE of +0.07%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to SASKEN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check SASKEN.NS's competition here
EXPLEOSOL.BO vs SASKEN.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, SASKEN.BO has a market cap of 27.5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while SASKEN.BO trades at ₹1,929.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas SASKEN.BO's P/E ratio is 51.02. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to SASKEN.BO's ROE of +0.07%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to SASKEN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check SASKEN.BO's competition here
EXPLEOSOL.BO vs PROTEAN.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, PROTEAN.BO has a market cap of 26.3B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while PROTEAN.BO trades at ₹630.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas PROTEAN.BO's P/E ratio is 29.12. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to PROTEAN.BO's ROE of +0.10%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to PROTEAN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check PROTEAN.BO's competition here
EXPLEOSOL.BO vs PROTEAN.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, PROTEAN.NS has a market cap of 26.3B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while PROTEAN.NS trades at ₹630.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas PROTEAN.NS's P/E ratio is 29.11. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to PROTEAN.NS's ROE of +0.10%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to PROTEAN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check PROTEAN.NS's competition here
EXPLEOSOL.BO vs DSSL.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, DSSL.BO has a market cap of 22.1B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while DSSL.BO trades at ₹1,892.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas DSSL.BO's P/E ratio is 26.30. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to DSSL.BO's ROE of +0.36%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to DSSL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check DSSL.BO's competition here
EXPLEOSOL.BO vs DSSL.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, DSSL.NS has a market cap of 22.1B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while DSSL.NS trades at ₹1,895.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas DSSL.NS's P/E ratio is 26.23. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to DSSL.NS's ROE of +0.36%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to DSSL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check DSSL.NS's competition here
EXPLEOSOL.BO vs SAKSOFT.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, SAKSOFT.BO has a market cap of 17.9B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while SAKSOFT.BO trades at ₹143.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas SAKSOFT.BO's P/E ratio is 14.79. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to SAKSOFT.BO's ROE of +0.20%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to SAKSOFT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check SAKSOFT.BO's competition here
EXPLEOSOL.BO vs SAKSOFT.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, SAKSOFT.NS has a market cap of 17.8B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while SAKSOFT.NS trades at ₹144.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas SAKSOFT.NS's P/E ratio is 14.73. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to SAKSOFT.NS's ROE of +0.20%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to SAKSOFT.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check SAKSOFT.NS's competition here
EXPLEOSOL.BO vs ACCELYA.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, ACCELYA.BO has a market cap of 16.8B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while ACCELYA.BO trades at ₹1,139.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas ACCELYA.BO's P/E ratio is 15.57. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to ACCELYA.BO's ROE of +0.35%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to ACCELYA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check ACCELYA.BO's competition here
EXPLEOSOL.BO vs ACCELYA.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, ACCELYA.NS has a market cap of 16.8B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while ACCELYA.NS trades at ₹1,142.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas ACCELYA.NS's P/E ratio is 15.56. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to ACCELYA.NS's ROE of +0.35%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to ACCELYA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check ACCELYA.NS's competition here
EXPLEOSOL.BO vs MMWL.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, MMWL.BO has a market cap of 15.5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while MMWL.BO trades at ₹13.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas MMWL.BO's P/E ratio is 274.00. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to MMWL.BO's ROE of +0.05%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to MMWL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check MMWL.BO's competition here
EXPLEOSOL.BO vs MCLOUD.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, MCLOUD.NS has a market cap of 15.3B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while MCLOUD.NS trades at ₹26.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas MCLOUD.NS's P/E ratio is 14.27. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to MCLOUD.NS's ROE of +0.20%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to MCLOUD.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check MCLOUD.NS's competition here
EXPLEOSOL.BO vs MCLOUD.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, MCLOUD.BO has a market cap of 15.3B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while MCLOUD.BO trades at ₹26.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas MCLOUD.BO's P/E ratio is 14.26. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to MCLOUD.BO's ROE of +0.20%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to MCLOUD.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check MCLOUD.BO's competition here
EXPLEOSOL.BO vs EXPLEOSOL.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, EXPLEOSOL.NS has a market cap of 14B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while EXPLEOSOL.NS trades at ₹905.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas EXPLEOSOL.NS's P/E ratio is 11.28. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to EXPLEOSOL.NS's ROE of +0.17%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to EXPLEOSOL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check EXPLEOSOL.NS's competition here
EXPLEOSOL.BO vs AURUM.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, AURUM.BO has a market cap of 13.7B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while AURUM.BO trades at ₹178.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas AURUM.BO's P/E ratio is 690.38. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to AURUM.BO's ROE of +0.00%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to AURUM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check AURUM.BO's competition here
EXPLEOSOL.BO vs AURUM.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, AURUM.NS has a market cap of 13.7B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while AURUM.NS trades at ₹178.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas AURUM.NS's P/E ratio is 690.35. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to AURUM.NS's ROE of +0.00%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to AURUM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check AURUM.NS's competition here
EXPLEOSOL.BO vs ORIENTTECH.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, ORIENTTECH.NS has a market cap of 12.5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while ORIENTTECH.NS trades at ₹278.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas ORIENTTECH.NS's P/E ratio is 58.79. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to ORIENTTECH.NS's ROE of +0.07%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to ORIENTTECH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check ORIENTTECH.NS's competition here
EXPLEOSOL.BO vs NINSYS.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, NINSYS.NS has a market cap of 12B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while NINSYS.NS trades at ₹655.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas NINSYS.NS's P/E ratio is 39.11. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to NINSYS.NS's ROE of +0.44%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to NINSYS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check NINSYS.NS's competition here
EXPLEOSOL.BO vs NINSYS.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, NINSYS.BO has a market cap of 12B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while NINSYS.BO trades at ₹648.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas NINSYS.BO's P/E ratio is 39.13. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to NINSYS.BO's ROE of +0.49%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to NINSYS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check NINSYS.BO's competition here
EXPLEOSOL.BO vs BGDL.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, BGDL.BO has a market cap of 11.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while BGDL.BO trades at ₹113.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas BGDL.BO's P/E ratio is 407.68. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to BGDL.BO's ROE of +0.07%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to BGDL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check BGDL.BO's competition here
EXPLEOSOL.BO vs 3IINFOTECH.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, 3IINFOTECH.BO has a market cap of 9.3B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while 3IINFOTECH.BO trades at ₹54.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas 3IINFOTECH.BO's P/E ratio is 111.67. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to 3IINFOTECH.BO's ROE of +0.00%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to 3IINFOTECH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check 3IINFOTECH.BO's competition here
EXPLEOSOL.BO vs XCHANGING.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, XCHANGING.NS has a market cap of 7.4B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while XCHANGING.NS trades at ₹66.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas XCHANGING.NS's P/E ratio is 12.86. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to XCHANGING.NS's ROE of +0.16%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to XCHANGING.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check XCHANGING.NS's competition here
EXPLEOSOL.BO vs XCHANGING.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, XCHANGING.BO has a market cap of 7.4B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while XCHANGING.BO trades at ₹66.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas XCHANGING.BO's P/E ratio is 12.86. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to XCHANGING.BO's ROE of +0.16%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to XCHANGING.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check XCHANGING.BO's competition here
EXPLEOSOL.BO vs VAKRANGEE.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, VAKRANGEE.BO has a market cap of 7.1B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while VAKRANGEE.BO trades at ₹6.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas VAKRANGEE.BO's P/E ratio is 65.20. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to VAKRANGEE.BO's ROE of +0.05%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to VAKRANGEE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check VAKRANGEE.BO's competition here
EXPLEOSOL.BO vs VAKRANGEE.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, VAKRANGEE.NS has a market cap of 7.1B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while VAKRANGEE.NS trades at ₹6.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas VAKRANGEE.NS's P/E ratio is 65.20. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to VAKRANGEE.NS's ROE of +0.05%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to VAKRANGEE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check VAKRANGEE.NS's competition here
EXPLEOSOL.BO vs ADSL.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, ADSL.BO has a market cap of 6.9B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while ADSL.BO trades at ₹124.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas ADSL.BO's P/E ratio is 21.48. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to ADSL.BO's ROE of +0.06%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to ADSL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check ADSL.BO's competition here
EXPLEOSOL.BO vs ADSL.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, ADSL.NS has a market cap of 6.9B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while ADSL.NS trades at ₹124.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas ADSL.NS's P/E ratio is 21.40. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to ADSL.NS's ROE of +0.06%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to ADSL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check ADSL.NS's competition here
EXPLEOSOL.BO vs MINDTECK.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, MINDTECK.BO has a market cap of 6.4B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while MINDTECK.BO trades at ₹205.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas MINDTECK.BO's P/E ratio is 22.78. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to MINDTECK.BO's ROE of +0.11%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to MINDTECK.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check MINDTECK.BO's competition here
EXPLEOSOL.BO vs MINDTECK.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, MINDTECK.NS has a market cap of 6.4B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while MINDTECK.NS trades at ₹204.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas MINDTECK.NS's P/E ratio is 22.77. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to MINDTECK.NS's ROE of +0.11%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to MINDTECK.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check MINDTECK.NS's competition here
EXPLEOSOL.BO vs ONWARDTEC.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, ONWARDTEC.NS has a market cap of 5.9B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while ONWARDTEC.NS trades at ₹270.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas ONWARDTEC.NS's P/E ratio is 13.40. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to ONWARDTEC.NS's ROE of +0.19%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to ONWARDTEC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check ONWARDTEC.NS's competition here
EXPLEOSOL.BO vs ONWARDTEC.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, ONWARDTEC.BO has a market cap of 5.9B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while ONWARDTEC.BO trades at ₹269.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas ONWARDTEC.BO's P/E ratio is 13.37. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to ONWARDTEC.BO's ROE of +0.19%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to ONWARDTEC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check ONWARDTEC.BO's competition here
EXPLEOSOL.BO vs INSPIRISYS.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, INSPIRISYS.BO has a market cap of 5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while INSPIRISYS.BO trades at ₹120.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas INSPIRISYS.BO's P/E ratio is 12.88. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to INSPIRISYS.BO's ROE of +0.57%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to INSPIRISYS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check INSPIRISYS.BO's competition here
EXPLEOSOL.BO vs INSPIRISYS.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, INSPIRISYS.NS has a market cap of 5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while INSPIRISYS.NS trades at ₹119.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas INSPIRISYS.NS's P/E ratio is 12.79. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to INSPIRISYS.NS's ROE of +0.57%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to INSPIRISYS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check INSPIRISYS.NS's competition here
EXPLEOSOL.BO vs DIGISPICE.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, DIGISPICE.BO has a market cap of 4.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while DIGISPICE.BO trades at ₹19.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas DIGISPICE.BO's P/E ratio is 72.96. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to DIGISPICE.BO's ROE of +0.09%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to DIGISPICE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check DIGISPICE.BO's competition here
EXPLEOSOL.BO vs CYBERTECH.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, CYBERTECH.NS has a market cap of 4.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while CYBERTECH.NS trades at ₹147.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas CYBERTECH.NS's P/E ratio is 13.97. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to CYBERTECH.NS's ROE of +0.14%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to CYBERTECH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check CYBERTECH.NS's competition here
EXPLEOSOL.BO vs CYBERTECH.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, CYBERTECH.BO has a market cap of 4.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while CYBERTECH.BO trades at ₹147.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas CYBERTECH.BO's P/E ratio is 13.96. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to CYBERTECH.BO's ROE of +0.14%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to CYBERTECH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check CYBERTECH.BO's competition here
EXPLEOSOL.BO vs DIGISPICE.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, DIGISPICE.NS has a market cap of 4.5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while DIGISPICE.NS trades at ₹19.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas DIGISPICE.NS's P/E ratio is 71.37. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to DIGISPICE.NS's ROE of +0.09%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to DIGISPICE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check DIGISPICE.NS's competition here
EXPLEOSOL.BO vs TERASOFT.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, TERASOFT.NS has a market cap of 4.3B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while TERASOFT.NS trades at ₹340.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas TERASOFT.NS's P/E ratio is 20.40. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to TERASOFT.NS's ROE of +0.19%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to TERASOFT.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check TERASOFT.NS's competition here
EXPLEOSOL.BO vs TERASOFT.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, TERASOFT.BO has a market cap of 4.2B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while TERASOFT.BO trades at ₹339.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas TERASOFT.BO's P/E ratio is 20.28. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to TERASOFT.BO's ROE of +0.19%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to TERASOFT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check TERASOFT.BO's competition here
EXPLEOSOL.BO vs XTGLOBAL.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, XTGLOBAL.BO has a market cap of 4.2B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while XTGLOBAL.BO trades at ₹32.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas XTGLOBAL.BO's P/E ratio is 47.70. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to XTGLOBAL.BO's ROE of +0.06%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to XTGLOBAL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check XTGLOBAL.BO's competition here
EXPLEOSOL.BO vs SIGMA.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, SIGMA.BO has a market cap of 4.1B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while SIGMA.BO trades at ₹38.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas SIGMA.BO's P/E ratio is 16.17. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to SIGMA.BO's ROE of +0.40%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to SIGMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check SIGMA.BO's competition here
EXPLEOSOL.BO vs SIGMA.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, SIGMA.NS has a market cap of 4.1B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while SIGMA.NS trades at ₹38.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas SIGMA.NS's P/E ratio is 16.03. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to SIGMA.NS's ROE of +0.40%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to SIGMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check SIGMA.NS's competition here
EXPLEOSOL.BO vs SILVERTUC.NS Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, SILVERTUC.NS has a market cap of 3.7B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while SILVERTUC.NS trades at ₹145.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas SILVERTUC.NS's P/E ratio is 51.83. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to SILVERTUC.NS's ROE of +0.25%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to SILVERTUC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check SILVERTUC.NS's competition here
EXPLEOSOL.BO vs SILVERTUC.BO Comparison May 2026
EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXPLEOSOL.BO stands at 14B. In comparison, SILVERTUC.BO has a market cap of 3.7B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹901.80, while SILVERTUC.BO trades at ₹146.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXPLEOSOL.BO currently has a P/E ratio of 11.30, whereas SILVERTUC.BO's P/E ratio is 51.64. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to SILVERTUC.BO's ROE of +0.25%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to SILVERTUC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check SILVERTUC.BO's competition here